Matinas Biopharma Holdings, Inc. · AMEX:MTNB
Matinas Biopharma — Investor Presentation (August 2014)
21 slides from Matinas Biopharma's investor presentation, Aug 8, 2014
Slide 1: Corporate Presentation
Corporate Presentation
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains "forward - looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, cash flow and other st
Slide 3: Team out of Reliant Pharmaceuticals with strong track record
Team out of Reliant Pharmaceuticals ( Lovaza ® ) with strong development & commercialization track record Unique and differentiating expertise in lipidomics and lipid chemistry Historical lack of innovation/investment in lipid - based therapies Initial focus on lower risk hypertriglyceridemia opport
Slide 4: High triglycerides: high risk
HIGH triglycerides Pancreatitis Cardiovascular Disease Type 2 Diabetes Fatty Liver Disease HIGH risk: 4
Slide 5: High number of patients with high triglycerides
HIGH number of patients with high triglycerides 5 ~4M ~65M (TG≥150mg/dl) (TG≥500mg/dl)
Slide 6: Lack of Good Prescription Options
2012 2013 Lack of Good Prescription Options 6 ~2.5M Rx/ yr lost US NON - LDL - LOWERING PRESCRIPTIONS – 2012 & 2013 Total Prescriptions TRx Source: IMS 35.0 32.5
Slide 7: Omega-3s lower triglyceride levels
The good news: Research shows strong evidence that Omega - 3s lower triglyceride levels 7
Slide 8: Not all Omega-3s are the same
Not all Omega - 3s are the same: Not all Rx Omega - 3s are the same: 8 COMMON OMEGA - 3S EPA DHA is associated with an increase in LDL cholesterol UNIQUE OMEGA - 3S DHA ALA ETA HPA LOVAZA (EPA and DHA) EPANOVA (EPA and DHA) VASCEPA (Pure EPA) High DHA Low DHA DPA SDA
Slide 9: MAT9001: next generation prescription-only omega-fatty acid medication
MAT9001 A next generation prescription - only omega - 3 fatty acid medication 9
Slide 10: MAT9001 – Unique engineered Omega composition
MAT9001 – Unique engineered Omega - 3 composition • Severe Hypertriglyceridemia (≥500mg/dL) • Highest potency • Unique Mechanism of Action • Trace amounts of DHA 10 EPA SPECIFICALLY DESIGNED TO TREAT DYSLIPIDEMIA DPA
Slide 11: Quality by Design
Quality by Design Our targeted development activities and related clinical investigations may yield a stronger therapeutic profile compared to the currently - existing therapies. 11 FASTING TG REDUCTION IN “FATTY ZUCKER” RAT MODEL Triglyceride Percent Reduction From Baseline – In Vivo -60% -50% -40%
Slide 12: Exploratory studies show potent effects on human triglyceride levels
0 0.5 1 1.5 2 0 1 2 3 4 5 Olive Oil (OO) OO + EPA 1 g/day OO + DPA 1 g/day 0 0.2 0.4 0.6 0.8 1 0 1 2 3 4 5 DPA VERSUS EPA IN POSTPRANDIAL TG CONTROL IN HUMANS Human Postprandial TG Levels ( mmol /L) over 5 hours, after 7 days treatment (3 - way cross - over, N=10) Exploratory studies show potent eff
Slide 13: Early data suggests synergy with statin usage
Early data suggests synergy with statin usage 13 STATIN INDUCED GENE - EXPRESSION COMPENSATORY EFFECTS AND N - 3 DOCOSAPENTAENOIC ACID (DPA) Relative levels of mRNA for HMG - CoA Reductase and PCSK9 in Rat Liver – In Vivo 0 0.5 1 1.5 2 2.5 3 Vehicle Only Vehicle + Statin DPA + statin 0 0.5 1 1.5 2 2
Slide 14: Short Track to Phase III
SHORT TRACK TO PHASE III Solid Safety Record with Omega - 3 Products MAT9001 Development Plan 2014 2015 2016 2017 API manufacturing, Animal Studies and IND Comparative PK Phase III in patients with Severe HTG (TG≥ 500mg/dL) PK/Drug Interaction Studies Additional Phase III ?? File NDA & FDA Review 14
Slide 15: Management by Design
Management by Design Roelof Rongen – President and CEO George Bobotas , PhD – Chief Scientific Officer Abdel Fawzy , PhD – EVP Pharmaceutical & Supply Chain Development Gary Gaglione , CPA – VP Finance, Acting CFO Jerome Jabbour , JD – Chief Business Officer & General Counsel Acquired by GlaxoSmithK
Slide 16: Board of Directors with Strong Pharma Experience
Board of Directors with Strong Pharma Experience Herbert Conrad, Chairman – Former President, Hoffmann LaRoche Pharmaceuticals – Co - Founder/Director: Reliant Pharmaceuticals – Chairman: Pharmasset , GenVec , Sapphire, Bone Care – Director: Celldex , Reliant, Dura, Sicor , Savient Stefano Ferrari,
Slide 17: We See an Attractive Market and Economics
We See… ~4 million adults with severe hypertriglyceridemia ~$200/month Lovaza/Vascepa pricing AN ATTRACTIVE MARKET… AND ATTRACTIVE ECONOMICS WITH A CLEAR NEED… 17 Lack of Satisfactory Rx Options
Slide 18: Designed for Market Appetite
Designed for Market Appetite $1.65B GSK acquired Reliant Pharmaceuticals in 2007 ~$105M Acasti [ACST] Market cap $323M + $125MM for milestone AstraZeneca acquired Omthera in 2013 after completion of Phase III 18 ~$300M Amarin [AMRN] Market cap Approved Pre - Phase III “ Capre ” Approved Approved “ E
Slide 19: Also in our Omega Pipeline
Also in our Omega - 3 pipeline MAT8800 – Proprietary Omega - 3 Discovery Program Treating Fatty Liver Disease NAFLD NASH • Common: 30% of U.S. population • A leading cause of cirrhosis • NO APPROVED TREATMENT OPTION MAT9001 Dyslipidemia & cardiovascular indications • Heart disease is the #1 killer 1
Slide 20: High Need, High Impact, High Value
20 + HIGH Need HIGH Impact HIGH Value =
Slide 21: Thank You
Our Stock: OTCBB: MTNB Thank You
Matinas BioPharma Holdings — Investor Presentation (August 2014) on 6ix